These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17017926)

  • 41. Quinolones in 2005: an update.
    Van Bambeke F; Michot JM; Van Eldere J; Tulkens PM
    Clin Microbiol Infect; 2005 Apr; 11(4):256-80. PubMed ID: 15760423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo diagnostic tests in adverse reactions to quinolones.
    Venturini Díaz M; Lobera Labairu T; del Pozo Gil MD; Blasco Sarramián A; González Mahave I
    J Investig Allergol Clin Immunol; 2007; 17(6):393-8. PubMed ID: 18088022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Possible involvement of DEC1 on the adverse effects of quinolone antibiotics.
    Shi X; Zheng Y; Ma W; Wang Y
    Toxicology; 2010 Apr; 271(1-2):1-4. PubMed ID: 20214949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetics of hypersensitivity drug reactions.
    Negrini S; Becquemont L
    Therapie; 2017 Apr; 72(2):231-243. PubMed ID: 28162244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Safety profile of antimicrobial agents].
    Hori S
    Yakugaku Zasshi; 2011; 131(10):1423-8. PubMed ID: 21963968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The fluoroquinolones.
    Walker RC
    Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Value of In Vitro Tests to DiminishDrug Challenges.
    Mayorga C; Doña I; Perez-Inestrosa E; Fernández TD; Torres MJ
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28590437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immediate allergic hypersensitivity to quinolones associates with neuromuscular blocking agent sensitization.
    Rouzaire P; Nosbaum A; Mullet C; Diot N; Dubost R; Bienvenu F; Guilloux L; Piriou V; Bienvenu J; Bérard F
    J Allergy Clin Immunol Pract; 2013; 1(3):273-9.e1. PubMed ID: 24565485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immediate hypersensitivity reactions to penicillins and other betalactams.
    Antúnez C; Martín E; Cornejo-García JA; Blanca-Lopez N; R-Pena R; Mayorga C; Torres MJ; Blanca M
    Curr Pharm Des; 2006; 12(26):3327-33. PubMed ID: 17017927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse drug reactions: types and treatment options.
    Riedl MA; Casillas AM
    Am Fam Physician; 2003 Nov; 68(9):1781-90. PubMed ID: 14620598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.
    Lai CC; Lee KY; Lin SW; Chen YH; Kuo HY; Hung CC; Hsueh PR
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):401-17. PubMed ID: 24579813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity.
    Lavergne SN; Park BK; Naisbitt DJ
    Curr Opin Allergy Clin Immunol; 2008 Aug; 8(4):299-307. PubMed ID: 18596585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Review and categorization of quinolone antibiotics].
    Benes J
    Klin Mikrobiol Infekc Lek; 2005 Feb; 11(1):4-14. PubMed ID: 15832257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypersensitivity reactions to ophthalmic products.
    Ventura MT; Viola M; Gaeta F; Di Leo E; Buquicchio R; Romano A
    Curr Pharm Des; 2006; 12(26):3401-10. PubMed ID: 17017934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors.
    Pichler WJ; Adam J; Watkins S; Wuillemin N; Yun J; Yerly D
    Int Arch Allergy Immunol; 2015; 168(1):13-24. PubMed ID: 26524432
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasmid-mediated quinolone resistance--current knowledge and future perspectives.
    Guan X; Xue X; Liu Y; Wang J; Wang Y; Wang J; Wang K; Jiang H; Zhang L; Yang B; Wang N; Pan L
    J Int Med Res; 2013 Feb; 41(1):20-30. PubMed ID: 23569126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
    Kocsis B; Domokos J; Szabo D
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.
    Naisbitt DJ; Gordon SF; Pirmohamed M; Park BK
    Drug Saf; 2000 Dec; 23(6):483-507. PubMed ID: 11144658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Understanding the mechanisms in accelerated drug reactions.
    Torres MJ; Salas M; Ariza A; Fernández TD
    Curr Opin Allergy Clin Immunol; 2016 Aug; 16(4):308-14. PubMed ID: 27285487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypersensitivity reactions to complementary and alternative medicine products.
    Ventura MT; Viola M; Calogiuri G; Gaeta F; Pesole O; Romano A
    Curr Pharm Des; 2006; 12(26):3393-9. PubMed ID: 17017933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.